肾功能亢进对耐甲氧西林金黄色葡萄球菌感染患儿万古霉素血药浓度及治疗效果的影响分析

何翠瑶; 秦嫣然; 刘成军; 任洁; 樊继山

doi:10.7499/j.issn.1008-8830.2019.09.012

PDF(1387 KB)

HTML

中国当代儿科杂志 ›› 2019, Vol. 21 ›› Issue (9) : 904-909. DOI: 10.7499/j.issn.1008-8830.2019.09.012

论著·临床研究

肾功能亢进对耐甲氧西林金黄色葡萄球菌感染患儿万古霉素血药浓度及治疗效果的影响分析

何翠瑶¹, 秦嫣然², 刘成军², 任洁³, 樊继山¹

作者信息 +

Effect of augmented renal clearance on plasma concentration of vancomycin and treatment outcome in children with methicillin-resistant Staphylococcus aureus infection

HE Cui-Yao¹, QIN Yan-Ran², LIU Cheng-Jun², REN Jie³, FAN Ji-Shan¹

Author information +

文章历史 +

摘要

目的研究肾功能亢进（ARC）对万古霉素治疗儿童耐甲氧西林金黄色葡萄球菌（MRSA）感染时的血药浓度、细菌学疗效及临床疗效的影响。方法回顾性研究2013年1月至2017年7月期间因明确MRSA感染使用万古霉素，并进行血药浓度监测的60例危重患儿的病例资料，根据肾小球滤过率（eGFR）分为ARC组（n=19）和肾功能正常组（n=41），对两组患儿在万古霉素使用、血药浓度及治疗效果等方面进行统计学比较分析。结果 ARC组的年龄主要分布在1~12岁，其体重和体表面积明显大于肾功能正常组（P < 0.05）。ARC组初始万古霉素血药谷浓度明显低于肾功能正常组，且ARC组达有效血药谷浓度（10~20 mg/L）比例低于肾功能正常组（P < 0.05）。两组在细菌学疗效评价和临床疗效评价方面比较差异均无统计学意义（P > 0.05），但ARC组的儿童重症监护室（PICU）住院时间及总住院时间明显长于肾功能正常组（P < 0.05）。结论 ARC明显降低MRSA感染患儿的万古霉素血药谷浓度，延长PICU住院时间及总住院时间。临床上应注意对ARC患儿施行个体化给药治疗。

Abstract

Objective To investigate the effect of augmented renal clearance (ARC) on plasma concentration of vancomycin, bacteriological outcome, and clinical outcome in children with methicillin-resistant Staphylococcus aureus (MRSA) infection treated by vancomycin. Methods A retrospective analysis was performed for the clinical data of 60 critically ill children who were treated with vancomycin due to MRSA infection from January 2013 to July 2017 and underwent plasma concentration monitoring. According to estimated glomerular filtration rate, these children were divided into an ARC group with 19 children and a normal renal function group with 41 children. The two groups were compared in terms of the use of vancomycin, plasma concentration of vancomycin, and treatment outcome. Results The children in the ARC group had an age of 1-12 years, and the ARC group had significantly higher body weight and body surface area than the normal renal function group (P < 0.05). Compared with the normal renal function group, the ARC group had a significantly lower initial trough concentration of vancomycin and a significantly lower proportion of children who achieved the effective trough concentration of vancomycin (10-20 mg/L) (P < 0.05). There were no significant differences in bacteriological outcome and clinical outcome between the two groups (P > 0.05), but the ARC group had significantly longer length of stay in the pediatric intensive care unit (PICU) and length of hospital stay than the normal renal function group (P < 0.05). Conclusions ARC can significantly reduce the trough concentration of vancomycin and prolong the length of PICU stay and the length of hospital stay in children with MRSA infection. Idividualized medication should be administered to children with ARC.

导出引用

何翠瑶, 秦嫣然, 刘成军, 任洁, 樊继山. 肾功能亢进对耐甲氧西林金黄色葡萄球菌感染患儿万古霉素血药浓度及治疗效果的影响分析[J]. 中国当代儿科杂志. 2019, 21(9): 904-909 https://doi.org/10.7499/j.issn.1008-8830.2019.09.012

HE Cui-Yao, QIN Yan-Ran, LIU Cheng-Jun, REN Jie, FAN Ji-Shan. Effect of augmented renal clearance on plasma concentration of vancomycin and treatment outcome in children with methicillin-resistant Staphylococcus aureus infection[J]. Chinese Journal of Contemporary Pediatrics. 2019, 21(9): 904-909 https://doi.org/10.7499/j.issn.1008-8830.2019.09.012

参考文献

[1] Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients:a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists[J]. Am J Health Syst Pharm, 2009, 66(1):82-98.
[2] 万古霉素临床应用剂量专家组. 万古霉素临床应用中国专家共识(2011版)[J]. 中国新药与临床杂志, 2011, 30(8):561-573.
[3] Sime FB, Udy AA, Roberts JA. Augmented renal clearance in critically ill patients:etiology, definition and implications for betalactam dose optimization[J]. Curr Opin Pharmacol, 2015, 24:1-6.
[4] 李庆云, 何娟, 余丽芳, 等. 一例重症胰腺炎伴肾功能亢进病人的药学服务[J]. 药学服务与研究, 2016, 16(6):433-437.
[5] 唐莲, 丁琦, 赵富丽, 等. 肾功能亢进患者抗感染治疗的药学监护[J]. 医药导报, 2017, 36(4):439-441.
[6] Huttner A, Von Dach E, Renzoni A, et al. Augmented renal clearance, low β-lactam concentrations and clinical outcomes in the critically ill:an observational prospective cohort study[J]. Int J Antimicrob Agents, 2015, 45(4):385-392.
[7] Claus BO, Hoste EA, Colpaert K, et al. Augmented renal clearance is a common finding with worse clinical outcome in critically ill patients receiving antimicrobial therapy[J]. J Crit Care, 2013, 28(5):695-700.
[8] De Cock PA, Standing JF, Barker CI, et al. Augmented renal clearance implies a need for increased amoxicillin-clavulanic acid dosing in critically ill children[J]. Antimicrob Agents Chemother, 2015, 59(11):7027-7035.
[9] Hirai K, Ihara S, Kinae A, et al. Augmented renal clearance in pediatric patients with febrile neutropenia associated with vancomycin clearance[J]. Ther Drug Monit, 2016, 38(3):393-397.
[10] Avedissian SN, Bradley E, Zhang D, et al. Augmented renal clearance using population-based pharmacokinetic modeling in critically ill pediatric patients[J]. Pediatr Crit Care Med, 2017, 18(9):e388-e394.
[11] Taketomo CK, Hodding JH, Kraus DM. Pediatric & Neonatal Dosage Handbook[M]. 25th. US:Wolters Kluwer, 2018:2196-2197.
[12] 梁晓宇,吴菊芳,杨敏婕,等.万古霉素治疗药物浓度监测队列研究[J].中国感染与化疗杂志, 2015, 15(5):472-478.
[13] 李博宇,崔向丽,王颖,等. 73例万古霉素血药浓度监测分析[J].中国临床药理学杂志, 2015, 31(12):1202-1204.
[14] Udy AA, Baptista JP, Lim NL, et al. Augmented renal clearance in the ICU:results of a multicenter observational study of renal function in critically ill patients with normal plasma creatinine concentrations[J]. Crit Care Med, 2014, 42(3):520-527.
[15] Campassi ML, Gonzalez MC, Masevicius FD, et al. Augmented renal clearance in critically ill patients:incidence, associated factors and effects on vancomycin treatment[J]. Rev Bras Ter Intensiva, 2014, 26(1):13-20.
[16] Baptista JP, Roberts JA, Sousa E, et al. Decreasing the time to achieve therapeutic vancomycin concentrations in critically ill patients:developing and testing of a dosing nomogram[J]. Crit Care, 2014, 18(6):654.
[17] Baptista JP, Sousa E, Martins PJ, et al. Augmented renal clearance in septic patients and implications for vancomycin optimisation[J]. Int J Antimicrob Agents, 2012, 39(5):420-423.
[18] Barriere SL, Stryjewski ME, Corey GR, et al. Effect of vancomycin serum trough levels on outcomes in patients with nosocomial pneumonia due to Staphylococcus aureus:a retrospective, post hoc, subgroup analysis of the Phase 3 ATTAIN studies[J]. BMC Infect Dis, 2014, 14:183.
[19] McNeil JC, Kok EY, Forbes AR, et al. Healthcare-associated Staphylococcus aureus bacteremia in children:evidence for reverse vancomycin creep and impact of vancomycin trough values on outcome[J]. Pediatr Infect Dis J, 2016, 35(3):263-268.
[20] Men P, Li HB, Zhai SD, et al. Association between the AUC0-24/MIC ratio of vancomycin and its clinical effectiveness:a systematic review and meta-analysis[J]. PLoS One, 2016, 11(1):e0146224.